

Name	Soulaima Chamat
Educational Background	1985 PhD in Immunology, Paris VII University, Paris, France 1982. Masters (DEA) in Immunology, Paris VII University Paris, France 1980 Bachelor in Natural Sciences, Faculty of Sciences, LU
Summary of career to date (150 -250 words)	1999 - present Teacher/researcher. Professor since 2002 Faculty of Medical Sciences, Lebanese University (LU) Co-founder and Co-director, Laboratory of Immunology and Vector-Borne Diseases Faculty of Public Health, LU 1995- 1998 Assistant Professor School of Medicine, American University of Beirut, Lebanon 1989- 1995 IDEC Pharmaceuticals Corporation, La Jolla, California, USA Post-doctoral fellow 1989-91. Research associate 1991-95 1986- 1991 Assistant Professor Faculty of Medical Sciences, LU
Research interests and specialty (List up to 5)	- Development of experimental models for vaccine evaluation in humanized mice - Development of novel vaccination platforms and protocols
Major accomplishments (100 words max.) (optional)	Teaching : Undergraduate and graduate - Basic immunology - Clinical immunology - Oral immunology - Virology Research -Supervised four PhD theses and several Masters theses - <i>At IDEC Pharmaceuticals Corporation, USA</i> Developed an anti-idiotypic monoclonal antibody as a therapeutic vaccine for HIV. Led the product to a phase 1 clinical trial. Was the

	<p>only post-doc at IDEC to earn a full-time position as a research associate in 1991.</p> <p><i>Academic services</i></p> <ul style="list-style-type: none"> - Member of the Steering committee for the WFME accreditation of the Faculty of Medical Sciences (2017-present) - Member of the Organizing Committee of biomedical international conferences held at the LU (2015-present) - Member of the Thesis committee, Faculty of Medical Sciences (2010-2017) - Academic coordinator of the Tempus project: « Organization of the Masters Curricula of Sciences, Technologies and Health at the Lebanese University » (2005-2009) - Member of the Central Board for Scientific Research at the LU (2003- 2007)
<p>List of publications (Preferable)</p>	<p><u><i>Review</i></u></p> <ul style="list-style-type: none"> - Saliba H, Heurtault B, Bouharoun-Tayoun H, Flacher V, Frisch B, Fournel S, Chamat S (2017). Enhancing tumor specific immune responses by transcutaneous vaccination, <i>Expert Rev. Vaccines</i>, 16:11, 1079-1094. <p><u><i>Original Articles</i></u></p> <ul style="list-style-type: none"> - Bou Karroum N, Moarbess G, Guichou JF, Bonnet PA, Patinote C, Bouharoun-Tayoun H, Chamat S, Cuq P, Diab-Assaf M, Kassab I, Deleuze-Masquefa C. (2019.) Novel and Selective TLR7 Antagonists among the Imidazo[1,2-a]pyrazines, Imidazo[1,5-a]quinoxalines, and Pyrazolo[1,5-a]quinoxalines Series. <i>J Med Chem.</i> 8;62(15):7015-7031. - Ghosn S., S.Chamat, E. Prieur, A.Stephan, P. Druilhe, H. Bouharoun-Tayoun. (2018). Evaluating Human Immune Responses for Vaccine Development in a Novel Human Spleen Cell- Engrafted NOD-SCID-IL2ryNull Mouse Model. <i>Front. Immunol.</i> 9:601.

- Fakh D, Akiki Z, Junker K, Medlej-Hashim M, Waked M, Salameh P, Holmskov U, Bouharoun-Tayoun H, Chamat S, Sorensen GL, Jounblat R. (2018). Surfactant protein D multimerization and gene polymorphism in COPD and asthma. *Respirology*. 23(3):298-305.
- Saliba H, Heurtault B, Bouharoun-Tayoun H, Flacher V, Frisch B, Fournel S, Chamat S (2017). Enhancing tumor specific immune responses by transcutaneous vaccination, *Expert Rev. Vaccines*, 16:11, 1079-1094.
- Akiki Z, Rava M, Diaz Gil O, Pin I, le Moual N, Siroux V, Guerra S, Chamat S, Matran R, Fitó M, Salameh P, Nadif R. (2017). Serum cytokine profiles as predictors of asthma control in adults from EGEA study. *Respir Med*. 125:57-64.
- Abou Jaoude S, Masri M, Rizk S, Chamat S, Farha J, Majzoub Z. (2017). Could Salivary Cyclosporine Dosage Replace the Whole Blood Cyclosporine Measurements in Renal Transplant Patients? *J Int Soc Prev Community Dent*. 7(3):136-41.
- Akiki Z, Fakh D, Jounblat R, Chamat S, Waked M, Holmskov U, Sorensen GL, Nadif R, Salameh P. (2016). Surfactant protein D, a clinical biomarker for chronic obstructive pulmonary disease with excellent discriminant values. *Exp Ther Med*. 11(3):723-730.
- Fakh D, Pilecki B, Schlosser A, Jepsen CS, Thomsen LK, Ormhøj M, Watson A, Madsen J, Clark HW, Barfod KK, Hansen S, Marcussen N, Jounblat R, Chamat S, Holmskov U, Sorensen GL. (2015). Protective effect of surfactant protein D treatment in 1,3-b-glucan-modulated allergic inflammation. *Am J Physiol Lung Cell Mol Physiol*. 309(11):1333-43.
- Tahtouh R; A-S Azzi; N Alaaeddine, S Chamat, H. Bouharoun-Tayoun; L. Wardi; I. Raad; R. Sarkis, N. Abou Antoun, G. Hilal. (2015). Telomerase Inhibition Decreases Alpha-fetoprotein Expression and Secretion by the Hepatocellular Carcinoma Cell Line HepG2/C3A. *PLoS One*, 10(3): e0119512.
- Yassine H, Kamareddine L, Chamat S, Christophides GK, Osta MA.(2014). A serine protease homolog negatively regulates TEP1 consumption in systemic

	<p>infections of the malaria vector <i>Anopheles gambiae</i>. <i>J Innate Immun.</i> 6(6):806-18.</p> <ul style="list-style-type: none"> - Gupta N, LeGoff J, Chamat S, Mercier-Delarue S, Touzelet O, Power UF, Kazatchkine MD, Simon F, Lacroix-Desmazes S, Bayry J, Kaveri SV (2013). Affinity-purified respiratory syncytial virus antibodies from intravenous immunoglobulin exert potent antibody-dependent cellular cytotoxicity. <i>PLoS One</i>;8(7):e69390. doi: 10.1371/journal.pone.0069390. - Haddad N, Mousson L, Vazeille M, Chamat S, Tayeh J, Osta MA, Failloux AB. (2012). <i>Aedes albopictus</i> in Lebanon, a potential risk of arboviruses outbreak. <i>BMC Infect Dis.</i> 12:300. - Chamat S, Salameh P, Haddad N, Berry A, Chedid P, Bouharoun-Tayoun H (2011). Protection of medical and paramedical university students in Lebanon against measles, mumps, rubella and varicella: Active measures are needed. 2011. <i>J Inf Pub Health</i> 2011 Aug;4(3):125-34. - Issa S, Walchshofer N, Kassab I, Termoss H, Chamat S, Geahchan A, Bouaziz Z. (2010). Synthesis and antiproliferative activity of oxazinocarbazole and N,N-bis(carbazolylmethyl)amine derivatives. <i>Eur J Med Chem.</i> 45(6):2567-77. - Ephrem A, Chamat S, Miquel C, Fisson S, Mouthon L, Caligiuri G, Delignat S, Elluru S, Bayry J, Lacroix-Desmazes S, Cohen JL, Benoît L, Salomon BL, Kazatchkine MD, Kaveri SV and Misra N. Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. <i>Blood</i> 2008; 111(2): 715. - Haddad N, Harbach RE, Chamat S and Bouharoun-Tayoun H. Presence of <i>Aedes albopictus</i> in Lebanon and Syria. <i>Journal of the American Mosquito Control Association</i> 2007 ; 23: 226-228. - Ephrem A, Misra N, Hassan G, Dasgupta S, Delignat S, Van Huyen JP, Chamat S, Prost F, Lacroix-Desmazes S, Kaveri SV and Kazatchkine MD. Immunomodulation of autoimmune and inflammatory diseases with intravenous immunoglobulin. <i>Clin Exp Med</i> 2005; 5(4): 135-40.
--	---

- Hanna J, Chahine R, Aftimos G, Nader M, Mounayar A, Esseily F and Chamat S. Protective effect of taurine against free radicals damage in the rat myocardium. *Toxicol Pathol* 2004; 56(3):189-94.
- Bouharoun-Tayoun H, Noun G, Druilhe P, Nakhlé C, Haddad N and Chamat S. *Plasmodium falciparum*: Production of Human Antibodies Specific for the MSP-3 Protein in the Hu-SPL-SCID Mouse. *J Exp Parasitol* 2004; 108: 47-52.
- Nakamura T, Kloetzer W S, Brams P, Hariharan K, Chamat S, Cao X, LaBarre MJ, Chinn P, Morena R A, Shestowsky WS, Li Y-P, Chenn A and Reff ME. In vitro IgE inhibition in B cells by anti-CD23 monoclonal antibodies is functionally dependent on the immunoglobulin Fc domain. *Int J Immunopharmacol* 2000 ; 22(2): 131-41.
- Heard C, Brams P, Walsh E E, Huynh T, Reff M, Owyang A, Shestowsky W, Chamat S. and Newman R. Two neutralizing human anti-RSV antibodies: Cloning, expression and characterization. *Mol Med* 1999; 5(1): 35-45.
- Chamat S, Walsh E, Anderson D, Osta M, Awaraji C, Pan L-Z, Ochi, J, Shuey S and Brams P. Human monoclonal antibodies isolated from spontaneous Epstein-Barr virus-transformed tumors of HU-SPL-SCID mice and specific for fusion protein display broad neutralizing activity toward Respiratory Syncytial Virus. *J Infect Dis* 1999; 180(2): 268-77.
- Brams P, Nguyen ML, Chamat S, Royston I and Morrow P. Antigen-specific IgG responses from naive human splenocytes: In vitro priming followed by antigen boost in the SCID mouse. *J Immunol* 1998; 160: 2051-8.
- Nwayri-Salti N, Nasr R, Haddad K, Chamat S and Usta J. Canine leishmaniasis in northern Lebanon. *Ann Trop Med Parasitol* 1997; 91: 221-2.
- Chamat S, Nara P, Berquist L, Whalley A, Morrow WJW, Kohler H. and Kang CY Two major groups of neutralizing anti-gp120 antibodies exist in HIV-infected individuals: evidence for epitope diversity around the CD4 attachment site. *J Immunol* 1992; 149: 649-54.

- Kang CY, Nara P, Chamat S, Caralli V, Chen A, Nguyen ML, Yoshiyama H, Morrow WJW, Ho D and Kohler H. Anti-idiotypic monoclonal antibody elicits broadly neutralizing anti-gp120 antibodies in monkeys. Proc Nat Acad Sci 1992; 89: 2546-50.
- Kang CY, Nara P, Chamat S, Caralli V, Ryskamp T, Haigwood N, Newman R and Kohler H. Evidence for non-V3-specific neutralizing antibodies that interfere with gp120/CD4 binding in human immunodeficiency virus 1-infected humans. Proc Nat Acad Sci 1991; 88: 6171-5.
- Morrow WJW, Williams WM, Whalley AS, Ryskamp T, Newman R, Kang CY, Chamat S, Kohler H and Kieber-Emmons T. Synthetic peptides from a conserved region of gp120 induce broadly reactive anti-HIV responses. Immunology 1991; 75: 557-64.
- Hoebeke J, Engelborghs Y, Chamat S and Strosberg AD. The immune response towards β -adrenergic ligands and their receptors. VII. Equilibrium and kinetics binding studies of l-alprenolol to a monoclonal anti-alprenolol antibody. Mol Immunol 1987; 24: 621-9.
- Chamat S, Hoebeke J, Emorine L, Guillet JG and Strosberg AD. The immune response towards β -adrenergic ligands and their receptors. VI. Idiotype of monoclonal anti-alprenolol antibodies. J Immunol 1986; 136: 3805-11.
- Strosberg AD, Guillet JG, Chamat S and Hoebeke J. Recognition of physiological receptors by anti-idiotypic antibodies: molecular mimicry of the ligand or cross-reactivity? Currents topics in Microb Immunol 1985; 119: 92-110.
- Hoebeke J, Chamat S, Marullo S, Guillet JG and Strosberg AD. Les anticorps monoclonaux comme agents pharmacologiques : Intérêt diagnostique et thérapeutique. Biosciences III 1984 ; no 13.
- Strosberg AD, Chamat S, Guillet JG, Lavaux B, Emorine L and Hoebeke J. Idiotype of catecholamine binding proteins. Annales d'immunologie de l'Institut Pasteur 1995 ; 1360 : 157-68.

Books and book chapters

- **عدوى الفيروس التاجي (كورونا) المستجد: دليل وإرشادات**. شامات، سلامه، صليبا، طيون، باسيل، بوهارون. منشورات الجامعة اللبنانية. نيسان ٢٠٢٠

- Chamat S, Immunol. Section in "Life Sciences". Third Year Secondary Cycle, Science Section. Ed: National Educational Center for Research and Development, Beirut, Lebanon. 2000.
- Strosberg AD, Chamat S, Guillet JG, Nahmias C, Hoebeke J and Emorine L. Idiotype of β -adrenergic ligand binding antibodies and receptors. In: "Idiotypes". D. Capra and Reichlin Eds., Academic Press. 1986. 139-55.
- Hoebeke J, Guillet JG, Chamat S and Strosberg AD. Anti-idiotypic antibodies for the study of membrane receptors: the double monoclonal antibody approach. In: "Investigation and exploitation of the antibody combining site". E. Reid Plenum Press, London. 1985. 115-22.
- Strosberg AD, Chamat S, Guillet JG, Schmutz A, Durieu O, Delavier C. and Hoebeke J. New immunological tools for the study of β -adrenergic receptors. In "Monoclonal anti-idiotypic antibodies as probes for receptor structure and function". C. Venter and L. Lindstrom Eds, Alan Liss, New York. 1984. 151-62.